Enlivex Therapeutics logo

Enlivex TherapeuticsNASDAQ: ENLV

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

31 July 2014

Next earnings report:

22 November 2024

Last dividends:

N/A

Next dividends:

N/A
$23.12 M
-85%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector
-73%vs. 3y high
35%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 63 min ago
$1.08$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ENLV Latest News

Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know
zacks.com31 October 2024 Sentiment: POSITIVE

Enlivex Therapeutics (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
globenewswire.com30 October 2024 Sentiment: POSITIVE

Nes-Ziona, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Japanese Patent Office issued a notice of allowance for patent application number 2022-512861 titled “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. Once issued, the resulting patent will provide Enlivex with added intellectual property (IP) protection through at least 2040. The Company expects that this new patent will be formally issued in Japan by the end of the second quarter of 2025.

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
globenewswire.com24 September 2024 Sentiment: POSITIVE

Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed an interim data review at the conclusion of the Phase I safety run-in stage of the Company's ongoing Phase I/II clinical trial of Allocetra™ in up to 160 patients with moderate to severe knee osteoarthritis. Patients in the Phase I safety run-in were treated with three sequential injections of Allocetra™ at escalating doses, and no serious adverse reactions were reported during or following the treatment. Following review of the data, the DSMB confirmed that the safety profile of Allocetra™ allows the Company to move forward to the Phase II stage of the Phase I/II trial, which is a double-blind, randomized evaluation of the safety and efficacy of intra-articular knee injections of Allocetra™ compared to placebo. The DSMB has also indicated that in light of the observed safety profile, the Phase II stage may proceed with the highest dose of Allocetra™ injections tested in the Phase I safety run-in.

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
globenewswire.com17 June 2024 Sentiment: POSITIVE

Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of AllocetraTM into the knee as a “last resort” Three-month data readout showed a significant reduction in pain and a favorable safety profile Pain reduction: patients reported an average pain reduction of 64% from baseline Complete Pain Resolution: 33% of patients reported complete pain relief, from an average pain level of 9 to a pain level of 0; pain scale used in the study ranged from 0 (no pain) to 10 (maximum pain) Avoidance of Surgery: 89% of patients did not proceed with knee replacement surgery at three months post-injection Safety: No severe adverse events related to Allocetra™ were reported Ness-Ziona, Israel, June 17, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today released a positive interim data readout from a Phase I/II investigator-initiated clinical trial of AllocetraTM in patients with end-stage knee osteoarthritis who had been indicated for knee replacement surgery.

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
globenewswire.com29 May 2024 Sentiment: POSITIVE

Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of $1.40 per ordinary share (or ordinary share equivalents in lieu thereof) and associated warrants, for aggregate gross proceeds of approximately $5.0 million.

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
Zacks Investment Research15 April 2024 Sentiment: NEGATIVE

Enlivex (ENLV) drops in value following the release of varied findings from a Phase II trial assessing its primary drug as a potential therapy for sepsis.

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
GlobeNewsWire11 April 2024 Sentiment: POSITIVE

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”) has announced that it will be holding a conference call and webcast on April 12, 2024, at 8:30am ET (15:30 IL time) to discuss the topline results from its Phase II trial of Allocetra™ in patients with sepsis, with 120 patients enrolled. Members of Enlivex's leadership team will be discussing the results during the call, followed by a live Q&A session.

Enlivex to Present at the 2023 Jefferies Healthcare Conference
GlobeNewsWire06 June 2023 Sentiment: POSITIVE

Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the 2023 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 11:30 AM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff281/enlv/1860430, and will be archived for 90 days.

What type of business is Enlivex Therapeutics?

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

What sector is Enlivex Therapeutics in?

Enlivex Therapeutics is in the Healthcare sector

What industry is Enlivex Therapeutics in?

Enlivex Therapeutics is in the Biotechnology industry

What country is Enlivex Therapeutics from?

Enlivex Therapeutics is headquartered in Israel

When did Enlivex Therapeutics go public?

Enlivex Therapeutics initial public offering (IPO) was on 31 July 2014

What is Enlivex Therapeutics website?

https://www.enlivex.com

Is Enlivex Therapeutics in the S&P 500?

No, Enlivex Therapeutics is not included in the S&P 500 index

Is Enlivex Therapeutics in the NASDAQ 100?

No, Enlivex Therapeutics is not included in the NASDAQ 100 index

Is Enlivex Therapeutics in the Dow Jones?

No, Enlivex Therapeutics is not included in the Dow Jones index

When was Enlivex Therapeutics the previous earnings report?

No data

When does Enlivex Therapeutics earnings report?

The next expected earnings date for Enlivex Therapeutics is 22 November 2024